Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)

- The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects

- The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akcea Therapeutics Inc

Ardelyx Inc

AstraZeneca Plc

Betagenon AB

BioElectron Technology Corp

Bird Rock Bio Inc

Boehringer Ingelheim GmbH

Cadila Healthcare Ltd

Can-Fite BioPharma Ltd ...

Akcea Therapeutics Inc

Ardelyx Inc

AstraZeneca Plc

Betagenon AB

BioElectron Technology Corp

Bird Rock Bio Inc

Boehringer Ingelheim GmbH

Cadila Healthcare Ltd

Can-Fite BioPharma Ltd

Carmot Therapeutics Inc

Cerenis Therapeutics Holding SA

Corcept Therapeutics Inc

Dr. Falk Pharma GmbH

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

Eternygen GmbH

Evgen Pharma Plc

F. Hoffmann-La Roche Ltd

Galmed Pharmaceuticals Ltd

Gemphire Therapeutics Inc

GemVax & KAEL Co Ltd

Gilead Sciences Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Hanmi Pharmaceuticals Co Ltd

HemoShear Therapeutics, LLC

Huons Global Co Ltd

Immuron Ltd

Inventiva

Ionis Pharmaceuticals Inc

Kinomedica Pty Ltd

Kowa Co Ltd

Kyorin Pharmaceutical Co Ltd

MallInckrodt Plc

Metacrine Inc

Mina Therapeutics Ltd

Novartis AG

NuSirt Biopharma Inc

Pfizer Inc

Phenex Pharmaceuticals AG

Renova Therapeutics Inc

Ritter Pharmaceuticals Inc

Sancilio & Company Inc

Shenzhen HighTide Biopharmaceutical Ltd

T3D Therapeutics Inc

TaiwanJ Pharmaceuticals Co Ltd

TCM Biotech International Corp

Theratechnologies Inc

Tiziana Life Sciences Plc

Viking Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Non Alcoholic Fatty Liver Disease (NAFLD) – Overview

Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Development

Non Alcoholic Fatty Liver ...

Table of Contents

Introduction

Non Alcoholic Fatty Liver Disease (NAFLD) – Overview

Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Development

Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Assessment

Non Alcoholic Fatty Liver Disease (NAFLD) – Companies Involved in Therapeutics Development

Non Alcoholic Fatty Liver Disease (NAFLD) – Drug Profiles

Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects

Non Alcoholic Fatty Liver Disease (NAFLD) – Discontinued Products

Non Alcoholic Fatty Liver Disease (NAFLD) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2019

Number of Products under Development by Companies, H1 ...

List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Akcea Therapeutics Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Ardelyx Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by AstraZeneca Plc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Betagenon AB, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by BioElectron Technology Corp, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Bird Rock Bio Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Boehringer Ingelheim GmbH, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Cadila Healthcare Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Can-Fite BioPharma Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Carmot Therapeutics Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Cerenis Therapeutics Holding SA, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Corcept Therapeutics Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Dr. Falk Pharma GmbH, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by DURECT Corp, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Eli Lilly and Co, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Enanta Pharmaceuticals Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Eternygen GmbH, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Evgen Pharma Plc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Galmed Pharmaceuticals Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Gemphire Therapeutics Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by GemVax & KAEL Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Gilead Sciences Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by HemoShear Therapeutics, LLC, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Huons Global Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Immuron Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Inventiva, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Ionis Pharmaceuticals Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Kinomedica Pty Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Kowa Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by MallInckrodt Plc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Metacrine Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Mina Therapeutics Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Novartis AG, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by NuSirt Biopharma Inc, H1 2019

List of Figures

List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2019

Number of Products under Development by Companies, H1 ...

List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports